知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

1612 records (took 0.056 seconds)

    Fusion polymerases
    111.
    发明授权
    Fusion polymerases 有权

    公开(公告)号：US10351831B2

    公开(公告)日：2019-07-16

    申请号：US15801114

    申请日：2017-11-01

    Applicant: Bio-Rad Laboratories, Inc.

    Inventor： Yan Wang ,  Man Cheng

    IPC: C12N9/12 ,  C12Q1/686 ,  C12N9/22

    Abstract: Fusion polypeptides having a heterologous 5′-3′ exonuclease domain linked to a polymerase that does not naturally have 5′-3′ exonuclease activity, as well as methods of their use are provided. Other aspects are also disclosed.

    Immunoblotting systems and methods
    112.
    发明授权
    Immunoblotting systems and methods 有权

    公开(公告)号：US10330675B2

    公开(公告)日：2019-06-25

    申请号：US15003536

    申请日：2016-01-21

    Applicant: Bio-Rad Laboratories, Inc.

    Inventor： Ning Liu

    IPC: G01N33/543

    Abstract: Immunoblotting systems and method are provided. In one embodiment, the method may be achieved by applying an antibody solution to a surface of a membrane having an optically detectable protein and a target protein transferred thereon, wherein the application of the antibody solution is guided by a signal emitted from the optically detectable protein; and detecting the target protein. Systems and other methods are also described and illustrated.

    Method and system for liquid chromatography data analysis
    115.
    发明授权
    Method and system for liquid chromatography data analysis 有权

    公开(公告)号：US10261058B2

    公开(公告)日：2019-04-16

    申请号：US14592308

    申请日：2015-01-08

    Applicant: Bio-Rad Laboratories, Inc.

    Inventor： Jeff Habel

    IPC: G01N33/48 ,  G01N33/50 ,  G01N30/86 ,  G06F19/18 ,  G01N30/74 ,  G01N30/46

    Abstract: One embodiment of the invention is directed to a method of analyzing liquid chromatography data. The method comprises collecting, by a data processing system, first volume fractions data from a first liquid chromatography column for a first absorbance wavelength of light λ1 from a first run of a liquid chromatography process on a mixture, wherein the first liquid chromatography column screens for a first characteristic of the mixture. The method further comprising, normalizing a first relative peak area for a first volume of a component of interest in the mixture for the first absorbance wavelength λ1 to obtain a first set of purity quotient values PQ1, collecting second volume fractions data from a second liquid chromatography column for a second absorbance wavelength of light λ2 from a second run of a liquid chromatography process on the mixture, wherein the second liquid chromatography column screens for a second characteristic of the mixture, normalizing a second relative peak area for the second volume of the component of interest in the mixture for the second absorbance wavelength λ2 to obtain a second set of purity quotient values PQ2, storing the values PQ1 and PQ2 in a memory, calculating a difference between values PQ1 and PQ2 for each volume fraction location of the first and second volumes to obtain a first set of purity quotient difference (“PQD”) values, displaying in a graphical display the first set of PQD values, and determining which volume fractions to pool together based on the display of the first set of PQD values.

    Using patient risk in analysis of quality control strategy for lab results
    117.
    发明授权
    Using patient risk in analysis of quality control strategy for lab results 有权

    公开(公告)号：US10161947B2

    公开(公告)日：2018-12-25

    申请号：US14702019

    申请日：2015-05-01

    Applicant: Bio-Rad Laboratories, Inc.

    Inventor： John Christopher Yundt-Pacheco ,  Lakshmi Kuchipudi ,  Curtis Alan Parvin

    IPC: G01N35/00 ,  G16H50/30 ,  G06F19/00

    Abstract: Methods, apparatuses, and systems are disclosed for analyzing quality control (QC) strategies that are applied to testing processes an analyte in order to meet an acceptable level of probability of patient harm that could result from incorrect test results. The measure of patient harm takes into account severity of patient harm, as well as its occurrence. Methods include calculating, based on the parameters of the QC strategies and the test apparatus, an expected number of incorrect final results E(Nuf) due to a test system failure. The value of E(Nuf) can be used as part of a calculation of a predicted level of probability patient harm. The ratio of the acceptable level of probability of patient harm to the predicted level of probability patient harm can determine the adequacy of the QC strategies.

    Optimized spectral matching and display
    118.
    发明授权
    Optimized spectral matching and display 有权

    公开(公告)号：US10152519B2

    公开(公告)日：2018-12-11

    申请号：US15060260

    申请日：2016-03-03

    Applicant: Bio-Rad Laboratories, Inc.

    Inventor： Karl Nedwed ,  Ty Abshear

    IPC: G06F17/30 ,  G06K9/52 ,  G06K9/62 ,  G06T11/20 ,  G01N21/35 ,  G06K9/46 ,  G01N21/552

    Abstract: Systems, methods, and apparatuses are provided for identifying an optimal spectral match and potentially display the compared spectra. A sample spectrum of a sample substance can be compared to reference spectra to identify matches, thereby determining possibilities for what the sample substance is. Correction parameter(s) may be used for the sample spectrum and/or the reference spectrum. Initial value(s) for the correction parameter(s) can be applied to the sample spectrum and/or a reference spectrum, and a similarity score can be determined. The value(s) for the correction parameter(s) can be updated and iteratively improved to provide an optimal similarity score that satisfies a convergence criterion. Data about the reference substances having optimal similarity scores that are above a threshold can be output to a user, e.g., the reference spectra can overlay the sample spectrum. A user can then make a final determination of which reference substance corresponds to the sample substance.

Patent Agency Ranking